MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering glucose, ketone and combined monitoring; "Act Earlier: From Insight to Intervention," exploring multimodal sensing and insulin delivery; and "Go Further: Realizing the Unimagined," looking toward broader biosensi

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression, accompanied by definitive tissue histopathological remodeling Concordant positive trajectories observed across motor and pulmonary functional endpoints Favorable safety and tolerability profile demonstrated, wi

SHANGHAI and HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that it will present the latest preclinical results of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstr

RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with KRAS/NRAS/BRAF triple wild-type tumors External control analysis showed higher weighted ORR and statistically significant improvements in PFS versus conventional care in both KRAS-mutated and KRAS wild-type subgroups BOSTON--(BUSINESS WIRE)-- $VSTM #CancerResearch --Verastem Oncology (Nasdaq: VSTM), a bi

This Week's Top 5 Stories in Healthcare This week’s top stories include GE HealthCare’s new AI Chief, BCG’s longevity market warning and Fresenius and NHS’ UK-first net-zero dialysis centre 1. GE HealthCare Appoints Rodolphe Katra as Chief AI Officer GE HealthCare has appointed Rodolphe Katra as its new Global Chief AI Officer , as the medical technology company looks to expand its use of AI across devices, software and healthcare data. Rodolphe joins from Medtronic , where he served as Chief AI

Vitamin C may do more than support the immune system. In a phase 2 trial of people with precancerous or low risk blood cancers, daily vitamin C did not slow abnormal cell growth, but it was linked to favorable changes in inflammation and fewer serious complications. An exploratory follow up also found fewer deaths among participants taking vitamin C than among those receiving placebo.Vitamin C can increase the activity of cellular proteins known as TET enzymes, which help regulate whether certai

Scientists have identified an enzyme that may act as a natural defense against the worsening of fatty liver disease, which affects an estimated 100 million Americans. The enzyme, called UBE2N, helps liver cells clear away damaged mitochondria and break down fat, potentially preventing the inflammation, scarring, and cell damage associated with the more dangerous condition MASH.Researchers co-led by Cedars-Sinai Health Sciences University have identified an enzyme that may help protect the liver

VALENCIENNES, France--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano group and pioneer in the field of targeted alpha therapies for oncology, today announced the inauguration of its ATLab (Alpha Therapy Laboratory) Valenciennes, Europe’s first industrial-scale pharmaceutical facility dedicated to the production of lead-212-based radioligand therapies. The opening ceremony took place in Onnaing, France, in the presence of Claude Imauven, Chairman of the Board of Directors of Orano, Nicolas

Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety pro children ages 6 through 17 years First pediatric clinical trial builds on 5 prior adult BPZE1 clinical studies Demonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individuals No interference observed when BPZE1 co-administered with diphtheria and tetanus antigens WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD

Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively) Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who star